Vaginal deployment and tenofovir delivery by microbicide gels

Drug Delivery and Translational Research

Volumn 5, Issue 3, 2015, Pages 279-294

  Gao, Y ^a   Yuan, A ^a   Chuchuen, O ^a   Ham, A ^b   Yang, K H ^c   Katz, D F ^a,d  

^a Duke University   (United States)

^b ImQuest Biosciences   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Compartmental model; Gel; Microbicide; Pharmacodynamics; Pharmacokinetics; Tenofovir; Vagina

Indexed keywords

MICROBICIDE; TENOFOVIR; ADENINE; AGENTS USED INTRAVAGINALLY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG VEHICLE; GEL; PHOSPHONIC ACID DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; DIFFUSION COEFFICIENT; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG TRANSPORT; FLOW KINETICS; INTRAVAGINAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RATE CONSTANT; SHEAR RATE; SHEAR STRESS; STEADY STATE; VAGINA MUCOSA; ALGORITHM; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BIOLOGY; BIOTRANSFORMATION; CHEMISTRY; COMPARATIVE STUDY; DIFFUSION; DRUG ABSORPTION; DRUG FORMULATION; FEMALE; GEL; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MUCOSA; PHOSPHORYLATION; THERMODYNAMICS; TISSUE DISTRIBUTION; VAGINA; VISCOSITY;

ADENINE; ALGORITHMS; ANTI-HIV AGENTS; BIOTRANSFORMATION; COMPUTATIONAL BIOLOGY; CONVECTION; DIFFUSION; DRUG COMPOUNDING; FEMALE; GELS; HUMANS; MODELS, BIOLOGICAL; MUCOUS MEMBRANE; ORGANOPHOSPHONATES; PHARMACEUTICAL VEHICLES; PHOSPHORYLATION; TENOFOVIR; TISSUE DISTRIBUTION; VAGINA; VAGINAL ABSORPTION; VAGINAL CREAMS, FOAMS, AND JELLIES; VISCOSITY;

EID: 84928881208     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-015-0227-1     Document Type: Article

References (40)

1. Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet. 2007;369(9563):787–97. doi:10.1016/s0140-6736(07)60202-5.
2. Stone A. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov. 2002;1(12):977–85.
3. das Neves J, Sarmento B. Drug delivery and development of anti-HIV microbicides. CRC Press; 2014.
4. Justin-Temu M, Damian F, Kinget R, Van Den Mooter G. Intravaginal gels as drug delivery systems. J Womens Health (Larchmt). 2004;13(7):834–44.
5. Hendrix CW, Cao YJ, Fuchs EJ. Topical microbicides to prevent HIV: clinical drug development challenges. Annu Rev Pharmacol Toxicol. 2009;49:349–75. doi:10.1146/annurev.pharmtox.48.113006.094906.
6. Howett MK, Kuhl JP. Microbicides for prevention of transmission of sexually transmitted diseases. Curr Pharm Des. 2005;11(29):3731–46. doi:10.2174/138161205774580633.
7. Ball C, Krogstad E, Chaowanachan T, Woodrow KA. Drug-eluting fibers for HIV-1 inhibition and contraception. PLoS One. 2012;7(11):e49792. doi:10.1371/journal.pone.0049792.
8. Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74. doi:10.1126/science.1193748.
9. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C et al., editors. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). 20th Conference on Retroviruses and Opportunistic infections; 2013.
10. Rees H, Delany-Moretlwe S, Baron D, Lombard C, Gray G, Myer L et al. FACTS 001 Phase III trial of pericoital tenofovir 1% gel for HIV prevention in women CROI; 2/23/2015; Seattle, Washington 2015. p. 26LB.
11. Morrow KM, Fava JL, Rosen RK, Vargas S, Shaw JG, Kojic EM et al. Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties. Aids Research and Human Retroviruses. 2014;30 (1):78-91. doi:DOI 10.1089/aid.2013.0099.
12. Mahan ED, Zaveri T, Ziegler GR, Hayes JE. Relationships between perceptual attributes and rheology in over-the-counter vaginal products: a potential tool for microbicide development. PLoS One. 2014;9(9), e105614. doi:10.1371/journal.pone.0105614.
13. Saltzman WM. Drug delivery: engineering principles for drug therapy. topics in chemical engineering. Oxford England. New York: Oxford University Press; 2001.
14. Gao Y, Katz DF. Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel. PLoS One. 2013;8(9), e74404. doi:10.1371/journal.pone.0074404.
15. Anissimov YG, Jepps OG, Dancik Y, Roberts MS. Mathematical and pharmacokinetic modelling of epidermal and dermal transport processes. Adv Drug Deliver Rev. 2013;65(2):169–90. doi:10.1016/j.addr.2012.04.009.
16. Pontrelli G, de Monte F. A two-phase two-layer model for transdermal drug delivery and percutaneous absorption. Math Biosci. 2014;257:96–103. doi:10.1016/j.mbs.2014.05.001.
17. Kieweg SL, Katz DF. Squeezing flows of vaginal gel formulations relevant to microbicide drug delivery. J Biomech Eng-Trans Asme. 2006;128(4):540–53. doi:10.1115/1.2206198.
18. Szeri AJ, Park SC, Verguet S, Weiss A, Katz DF. A model of transluminal flow of an anti-HIV microbicide vehicle: combined elastic squeezing and gravitational sliding. Phys Fluids. 2008;20(8):083101. doi:10.1063/1.2973188.
19. Tasoglu S, Park SC, Peters JJ, Katz DF, Szeri AJ. The consequences of yield stress on deployment of a non-Newtonian anti-HIV microbicide gel. J Non-Newton Fluid. 2011;166(19-20):1116–22. doi:10.1016/j.jnnfm.2011.06.007.
20. Tasoglu S, Peters JJ, Park SC, Verguet S, Katz DF, Szeri AJ. The effects of inhomogeneous boundary dilution on the coating flow of an anti-HIV microbicide vehicle. Phys Fluids. 2011;23(9):093101. doi:10.1063/1.3633337.
21. Tasoglu S, Katz DF, Szeri AJ. Transient spreading and swelling behavior of a gel deploying an anti-HIV topical microbicide. J Nonnewton Fluid Mech. 2012;187-188:36–42. doi:10.1016/j.jnnfm.2012.08.008.
22. Katz DF, Gao Y, Kang M. Using modeling to help understand vaginal microbicide functionality and create better products. Drug Del Translat Res. 2011;1(3):256–76.
23. Anwar MR, Camarda KV, Kieweg SL. Mathematical model of microbicidal flow dynamics and optimization of rheological properties for intra-vaginal drug delivery: role of tissue mechanics and fluid rheology. J Biomech. (0). doi:http://dx.doi.org/10.1016/j.jbiomech.2015.01.049.
24. Kiser PF, Mahalingam A, Fabian J, Smith E, Damian FR, Peters JJ, et al. Design of tenofovir-UC781 combination microbicide vaginal gels. J Pharmaceut Sci. 2012;101(5):1852–64. doi:10.1002/Jps.23089.
25. Mahalingam A, Smith E, Fabian J, Damian FR, Peters JJ, Clark MR, et al. Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res. 2010;27(11):2478–91. doi:10.1007/s11095-010-0244-1.
26. Ham AS, Ugaonkar SR, Shi LJ, Buckheit KW, Lakougna H, Nagaraja U, et al. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J Pharm Sci. 2012;101(4):1423–35. doi:10.1002/Jps.23026.
27. Schwartz JL, Rountree W, Kashuba ADM, Brache V, Creinin MD, Poindexter A, et al. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One. 2011;6(10), e25974. doi:10.1371/journal.pone.0025974.
28. Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One. 2013;8(1), e55013. doi:10.1371/journal.pone.0055013.
29. Barnhart KT, Izquierdo A, Pretorius ES, Shera DM, Shabbout M, Shaunik A. Baseline dimensions of the human vagina. Hum Reprod. 2006;21(6):1618–22. doi:10.1093/humrep/del022.
30. Pendergrass PB, Belovicz MW, Reeves CA. Surface area of the human vagina as measured from vinyl polysiloxane casts. Gynecol Obstet Investig. 2003;55(2):110–3. doi:10.1159/000070184.
31. Kieweg SL, Katz DF. Interpreting properties of microbicide drug delivery gels: analyzing deployment kinetics due to squeezing. J Pharm Sci. 2007;96(4):835–50. doi:10.1002/Jps.20774.
32. Owen DH, Peters JJ, Katz DF. Rheological properties of contraceptive gels. Contraception. 2000;62(6):321–6.
33. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate—clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595–612.
34. Mathworks. MATLAB. 7.11.0 ed. Natick, Massachusetts: MathWorks Inc.; 2010.
35. Patton DL, Thwin SS, Meier A, Hooton TM, Stapleton AE, Eschenbach DA. Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. Am J Obstet Gynecol. 2000;183(4):967–73. doi:10.1067/mob.2000.108857.
36. Chuchuen O, Henderson MH, Sandros MG, Kashuba ADM, Katz DF. Transport and transport properties of tenofovir from microbicide gels into vaginal tissue: analysis using raman spectroscopy. Aids Res Hum Retroviruses. 2014;30(S1):A59–60. doi:10.1089/aid.2014.5106.abstract.
37. Hawkins T, Veikley W, St. Claire RLI, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. JAIDS J Acq Imm Def Synd. 2005;39(4):406–11.
38. Vermund SH, Van Damme L. HIV prevention in women: next steps. Science. 2011;331(6015):284. doi:10.1126/science.331.6015.284-a.
39. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemotherap. 2011;66(2):240–50. doi:10.1093/jac/dkq447.
40. Louissaint NA, Cao YJ, Skipper PL, Liberman RG, Tannenbaum SR, Nimmagadda S, et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. Aids Res Hum Retroviruses. 2013;29(11):1443–50. doi:10.1089/aid.2013.0044.